Summit Therapeutics (SMMT) Misses Q2 EPS by 3c

Summit Therapeutics (NASDAQ: SMMT) reported Q2 EPS of (GBP0.12), GBP0.03 worse than the analyst estimate of (GBP0.09).

For earnings history and earnings-related data on Summit Therapeutics (SMMT) click here.

You May Also Be Interested In

• Lyntris opens at $15.50, below IPO price of $17.50
• Analog Devices climbs as fiscal Q3 results, Q4 outlook beat forecasts
• Marvell signs major custom silicon deal with Google, sell-side comments